Back to Browse Journals » Vascular Health and Risk Management » Volume 4 » Issue 5

Maintenance of improved lipid levels following attendance at a cardiovascular risk reduction clinic: a 10-year experience

Authors Glen J Pearson, Kari L Olson, Nicole E Panich, Sumit R Majumdar, Ross T Tsuyuki, et al

Published 10 October 2008 Volume 2008:4(5) Pages 1127—1135


Review by Single-blind

Peer reviewer comments 2

Glen J Pearson1,5, Kari L Olson6, Nicole E Panich1, Sumit R Majumdar2,5, Ross T Tsuyuki1,4, Dawna M Gilchrist2,5, Ali Damani4, Gordon A Francis3,5

The MILLARR Study (Maintenance of Improved Lipid Levels Following Attendance at a Cardiovascular Risk Reduction Clinic) 1Department of Medicine, Divisions of Cardiology; 2General Internal Medicine; 3Endocrinology and Metabolism; Faculty of Pharmacy and Pharmaceutical Sciences; 4University of Alberta, Edmonton, Alberta, Canada; 5Cardiovascular Risk Reduction Clinic (CRRC), University of Alberta Hospital, Edmonton, Alberta, Canada; 6University of Colorado Health Sciences Center, Denver, Colorado, USA; 7Family Medicine (Private Practice), Calgary, Alberta, Canada

Background: Specialty cardiovascular risk reduction clinics (CRRC) increase the proportion of patients attaining recommended lipid targets; however, it is not known if the benefits are sustained after discharge. We evaluated the impact of a CRRC on lipid levels and assessed the long-term effect of a CRRC in maintaining improved lipid levels following discharge.

Methods: The medical records of consecutive dyslipidemic patients discharged >6 months from a tertiary hospital CRRC from January 1991 to January 2001 were retrospectively reviewed. The primary outcome was the change in patients’ lipid levels between the final CRRC visit and the most recent primary care follow-up. A worst-case analysis was conducted to evaluate the potential impact of the patients in whom the follow-up lipid profiles post-discharge from the CRRC were not obtained.

Results: Within the CRRC (median follow-up = 1.28 years in 1064 patients), we observed statistically significant improvements in all lipid parameters. In the 411 patients for whom post-discharge lipid profiles were available (median follow-up = 2.41 years), there were no significant differences observed in low-density lipoprotein-cholesterol, total cholesterol (TC), or triglycerides since CRRC discharge; however, there were small improvements in high-density lipoprotein-cholesterol (HDL-C) and TC:HDL ratio (p < 0.05 for both). The unadjusted worst-case analysis (653 patients with no follow-up lipid profiles) demonstrated statistically significant worsening of all lipid parameters between CRRC discharge and the most recent follow-up. However, when the change in lipid parameters between the baseline and the most recent follow-up was assessed in this analysis, the changes in all lipid parameters were significantly improved (p < 0.05).

Conclusions: This study demonstrates that a CRRC can improve lipid levels and suggests that these benefits are sustained once patients are returned to the care of their primary physician.

Keywords: cardiovascular risk factors, dyslipidemia, outcomes, pharmacotherapy, secondary prevention

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 


Readers of this article also read:

Protection of adenovirus from neutralizing antibody by cationic PEG derivative ionically linked to adenovirus

Zeng Q, Han J, Zhao D, Gong T, Zhang Z, Sun X

International Journal of Nanomedicine 2012, 7:985-997

Published Date: 27 February 2012

Blood pressure-independent effect of candesartan on cardio-ankle vascular index in hypertensive patients with metabolic syndrome

Kanako Bokuda, Atsuhiro Ichihara, Mariyo Sakoda, et al

Vascular Health and Risk Management 2010, 6:571-578

Published Date: 5 July 2010

Long-acting nifedipine in the management of the hypertensive patient

Morgan E Snider, Donald S Nuzum, Angie Veverka

Vascular Health and Risk Management 2008, 4:1249-1257

Published Date: 5 December 2008

Effects of study design and trends for EVAR versus OSR

Robert Hopkins, James Bowen, Kaitryn Campbell, Gord Blackhouse, Guy De Rose, et al

Vascular Health and Risk Management 2008, 4:1011-1022

Published Date: 10 October 2008

Topical ophthalmic NSAIDs: a discussion with focus on nepafenac ophthalmic suspension

Bruce I Gaynes, Anne Onyekwuluje

Clinical Ophthalmology 2008, 2:355-368

Published Date: 6 June 2008

Silent cerebral infarction in chronic heart failure: Ischemic and nonischemic dilated cardiomyopathy

Guliz Kozdag, Ercument Ciftci, Dilek Ural, Tayfun Sahin, Macit Selekler, et al

Vascular Health and Risk Management 2008, 4:463-469

Published Date: 11 April 2008

False negative results in glaucoma detection with Heidelberg Retina Tomograph II

Catherine Deghislage, Lidwine Van Malderen, Thierry G Zeyen

Clinical Ophthalmology 2008, 2:153-157

Published Date: 7 March 2008

Anterior segment dysgenesis in a child with factor VII deficiency

Francis Beby, Sandrine Meunier, Pierre Cochat, Olivier Roche, Florent Aptel, et al

Clinical Ophthalmology 2007, 1:335-337

Published Date: 15 December 2007